The key to a powerful antibiotic's formation now clear
A powerful class of antibiotics called carbapenems can circumvent antibiotic resistance thanks to a particular chain of atoms in their structure. Now, a team of researchers from Penn State and Johns Hopkins University...
February 7, 2022
by WorldPharmaNews
Cellvera Receives $20M Order for COVID-19 Oral Antiviral Avigan
Favipiravir is a broad-spectrum oral antiviral drug that targets COVID-19 and 11 other infectious diseases.
January 25, 2022
by contractpharma
Angel Yeast Invests in New Enzyme Project
New green manufacturing base will be capable of 5,000 tons annual production output.
January 3, 2022
by pharmatimes
Enzyme Replacement Therapy Approved for Late-Onset Pompe Disease
Nexviazyme (avalglucosidase alfa-ngpt) was approved for the treatment of the rare inherited disorder late-onset Pompe disease in patients 1 year of age and older, the U.S. Food and Drug Administration announced Friday.
August 11, 2021
by drugs
Synthetic Biology Startup Allozymes Raises US $5 Million Seed Round to Deliver Sustainable, Scalable Manufacturing of Natural Ingredients
Allozymes, a Singapore-based, synthetic biology startup, announced today that it has raised US $5 million in a seed financing round led by Xora Innovation, the deep science investment arm of Temasek Holdings.
July 21, 2021
by prnasia
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Codexis, Inc.,today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing
June 11, 2021
by firstwordpharma
Gene therapy successfully treats rare immunodeficiency in paediatric patients
In three Phase I/II trials an experimental gene therapy caused all but two patients with severe combined immunodeficiency to acquire and retain robust immune function for more than two years.
May 13, 2021
by europeanpharmaceuticalreview
Researchers discover SARS-CoV-2 inhibitors
A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus.
March 5, 2021
by worldpharmanews
ACE2 protein protects against severe COVID-19
Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stronger immune response, according to new research from a University of Alberta-led team.
December 18, 2020
by worldpharmanews
Sekisui Diagnostics Invests in Biopharma CDMO Capacity
Investing £14.4 million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at its site in Maidstone, Kent.
August 5, 2020
by contractpharma
MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®
Based on its recent analysis of the European industrial enzymes market, Frost & Sullivan recognizes Finland-based MetGen with the 2019 European Technology Innovation Award for its enzyme technologies...
October 17, 2019
by En-CPhI.CN
Capsosomes: the revolutionary enzyme carriers
Capsosomes: the revolutionary enzyme carriers.
July 5, 2019
by europeanpharmaceuticalreview